stockrow
Saturday 7 November 2026
Export GRI’s income statement to Excel — free account
GRI Bio, Inc.
- EPS
- +97.5%
- Free cash flow
- +54.3%
Quarter to June 2026, against a year earlier
1.84
0.29
+18.71%
Follow GRI
Alert me
GRI Bio, Inc. (GRI) P/E ratio
GRI Bio, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2020 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| PBLA Panbela Therapeutics Inc. compare | n/m |
| CVKD Cadrenal Therapeutics, Inc. compare | n/m |
| LIMN Liminatus Pharma Inc. compare | n/m |
| ONCO Onconetix, Inc. compare | n/m |
| GRI GRI Bio, Inc. | n/m |
| ADXN Addex Therapeutics Ltd. Sponsored ADR compare | n/m |
| LIPO Lipella Pharmaceuticals Inc. compare | n/m |
| TRAW Traws Pharma, Inc. compare | n/m |
| SXTP 60 Degrees Pharmaceuticals Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)